These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23618722)

  • 1. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.
    Eurich DT; Simpson S; Senthilselvan A; Asche CV; Sandhu-Minhas JK; McAlister FA
    BMJ; 2013 Apr; 346():f2267. PubMed ID: 23618722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study.
    Weir DL; McAlister FA; Senthilselvan A; Minhas-Sandhu JK; Eurich DT
    JACC Heart Fail; 2014 Dec; 2(6):573-82. PubMed ID: 24998080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
    Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
    Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.
    Lage MJ; Fabunmi R; Boye KS; Misurski DA
    Adv Ther; 2009 Feb; 26(2):217-29. PubMed ID: 19219409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database.
    Cai B; Katz L; Alexander CM; Williams-Herman D; Girman CJ
    Int J Clin Pract; 2010 Nov; 64(12):1601-8. PubMed ID: 20946268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2010 Mar; 65(3):127-32. PubMed ID: 20411816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
    Giampietro O; Giampietro C; Bartola LD; Masoni MC; Matteucci E
    Drug Des Devel Ther; 2013; 7():99-104. PubMed ID: 23439744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon.
    Fairman KA; Curtiss FR
    J Manag Care Pharm; 2009 Oct; 15(8):696-700. PubMed ID: 19803560
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Adv Ther; 2010 Apr; 27(4):223-32. PubMed ID: 20464538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Zerilli T; Pyon EY
    Clin Ther; 2007 Dec; 29(12):2614-34. PubMed ID: 18201579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
    Chwieduk CM
    Drugs; 2011 Feb; 71(3):349-61. PubMed ID: 21319871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
    Soliman AR; Fathy A; Khashab S; Shaheen N; Soliman MA
    Exp Clin Transplant; 2013 Dec; 11(6):494-8. PubMed ID: 24344941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
    Lumb AN; Gallen IW
    Diabet Med; 2009 Feb; 26(2):189-90. PubMed ID: 19236626
    [No Abstract]   [Full Text] [Related]  

  • 18. Managed care perspective on three new agents for type 2 diabetes.
    VanDeKoppel S; Choe HM; Sweet BV
    J Manag Care Pharm; 2008 May; 14(4):363-80. PubMed ID: 18500914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)].
    Rabasseda X
    Drugs Today (Barc); 2011 Nov; 47 Suppl D():1-8. PubMed ID: 22439134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.